Neuroscience Clinical Trial Experience

The central nervous system affects physical and behavioral health in untold ways. Unraveling the field’s complexity requires an understanding that comes only from experience.

prcom_Asset 1ARROW

Breaking barriers in neuroscience

A nuanced approach to a uniquely complex field

Neurological outcomes can seldom be measured just by lab results. Having performed more than 250 studies across the field in the past five years, we have the hands-on experience and knowledgeable staff to provide the precise approach your trial needs and to anticipate and overcome the obstacles – for example, finding ways to manage screen failure rates in Alzheimer’s trials that reach as high as 70 percent.

Today is a fascinating time to work in neuroscience drug development as we help the most innovative sponsors unlock the mysteries of the central nervous system. Our neuroscience clinical research professionals leverage their background in a diverse range of psychiatric and neurological indications to ensure that we provide you with the best possible regulatory and scientific, medical, and operational delivery advice.

Why choose Premier?
  • Our work has touched more than 50,000 patients afflicted by just about every major central nervous system disorder
  • More than half of our work is in rare diseases
  • We have a history of breakthrough work, including the first post-traumatic stress disorder study in military veterans

PREMIER PERSPECTIVE

Operational challenges of neuroscience trials

It’s not surprising that neuroscience clinical trials – more so than trials in other medical specialties – face major challenges, both conceptual and practical.

WHITE PAPER

Rethinking LAIs

Use of long-acting injectable antipsychotics is often reserved for patients with chronic or treatment-refractory schizophrenia, but recent studies have consistently found a role for these treatments both soon after diagnosis and in the treatment of chronic disease.

Featured Resources

WEBINAR

WEBINAR

The Potential for Disease-Modifying Therapies in Parkinson’s Disease

Blog

Blog

New Research Highlights the Challenges of Studying Alzheimer’s Disease

Premier Insight

Premier Insight

#255: Merging Science and Nuance to Treat Post-Traumatic Stress Disorder

Premier Thought Leadership

Krista Armstrong

Senior Vice President, Clinical Development Services &, Global Head of Neuroscience

Dr. Armstrong’s primary therapeutic and operational expertise has had a specific emphasis on psychiatric indications such as ADHD, schizophrenia, mood disorders, ASD, eating disorders, substance use disorders and PTSD as well as neurological conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy and stroke.

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.